HQ Specialty Pharma v. Amneal Pharmaceuticals: Calcium Gluconate Injection Patent Resolved by Consent Judgment
HQ Specialty Pharma Corp. and WG Critical Care, LLC asserted US Patent No. 10,130,646 covering terminally sterilized Calcium Gluconate in sodium chloride injection bags against Amneal Pharmaceuticals in Delaware. The 671-day case closed with a consent judgment that dismissed all claims without prejudice but imposed a permanent injunction barring Amneal from commercializing its competing product for the life of the patent.
Injunction secured without merits ruling: a strategic win for plaintiffs
Filed on 11 October 2023 in the District of Delaware before Judge Maryellen Noreika, this infringement action was brought by HQ Specialty Pharma Corp. and WG Critical Care, LLC against Amneal Pharmaceuticals, Inc. The plaintiffs asserted a single patent — US10130646B1 — covering terminally sterilized Calcium Gluconate in sodium chloride injection bag products, a formulation used in clinical settings for hypocalcemia and cardiac resuscitation protocols. Amneal, a major generic and specialty pharmaceutical manufacturer, had developed competing injection bag products that plaintiffs alleged infringed the ‘646 patent.
The case closed on 12 August 2025 via a Stipulation and Consent Judgment filed jointly by the parties. All claims and counterclaims were dismissed without prejudice, meaning the merits were never formally adjudicated. Crucially, however, Amneal agreed to be permanently enjoined from making, importing, using, offering for sale, or selling its terminally sterilized Calcium Gluconate injection bag products in the United States for the remaining term of the ‘646 patent — unless licensed by the plaintiffs. Plaintiffs simultaneously waived all damages claims arising from Amneal’s pre-August 8, 2025 sales.
At 671 days, the case resolved before trial, suggesting the parties reached a commercial accommodation after substantive litigation posture was established. The mutual concessions — Amneal accepting an injunction, plaintiffs waiving past damages — are consistent with a negotiated resolution that prioritises market exclusivity over monetary recovery. The court retained jurisdiction to enforce the consent judgment, adding a compliance mechanism without requiring further litigation to initiate. What remains unknown from the public record is whether any licensing arrangement accompanies the injunction, and the commercial magnitude of Amneal’s pre-injunction sales.
Filing to Dismissed without Prejudice in 671 days
671 days — above the median for ANDA-adjacent pharmaceutical patent disputes in Delaware
Consent judgment without merits: injunction entered, damages waived
Dismissed without prejudice — but injunction survives
A dismissal without prejudice under a consent judgment means no court adjudicated whether the ‘646 patent was infringed or valid. The parties contractually agreed to the outcome. Critically, the injunction is a court-entered order — not merely a private settlement clause — giving plaintiffs a judicially enforceable mechanism to block Amneal’s product for the patent’s remaining term without proving infringement at trial.
No merits adjudicationMarket exclusivity secured without litigation risk
HQ Specialty Pharma and WG Critical Care achieved what patent holders most often pursue — exclusionary rights over a competitor’s product — without exposing the ‘646 patent to an invalidity adjudication. By waiving pre-August 2025 damages, they traded retrospective monetary recovery for a forward-looking, court-backed bar on Amneal’s commercialisation, preserving the patent’s enforceability against other potential challengers.
Injunction securedAmneal exits the market without invalidity finding
Amneal accepted a permanent injunction covering its Calcium Gluconate injection bag products for the life of the ‘646 patent, but avoided a merits ruling that could have triggered collateral estoppel on validity or infringement. The dismissal without prejudice and the explicit clause that the consent judgment ‘shall not act as an adjudication on the merits’ preserves Amneal’s theoretical ability to re-approach the market under a future license or patent expiry.
Injunction accepted, no merits lossConsent judgments as market-shaping tools in IV pharma
This outcome illustrates how patent holders in the sterile injectable space can leverage litigation to obtain injunctive relief and past-damages waivers simultaneously — effectively resetting the competitive landscape without full trial. For other manufacturers in the terminally sterilized IV bag segment, the court-retained jurisdiction and the patent’s continuing term signal that the exclusionary perimeter around the ‘646 patent remains active and enforceable.
Market exclusivity preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | HQ Specialty Pharma, Corp. | Company | Specialty pharmaceutical IP holders — asserting US10130646B1 on sterilized Calcium Gluconate IV bagsSearch in Eureka ↗ |
| Co-Plaintiff | Wg Critical Care, LLC | Company | Search in Eureka ↗ |
| Defendant | Amneal Pharmaceuticals, Inc. | Company | Amneal Pharmaceuticals, Inc. — generic and specialty pharma manufacturer of competing injection bag productsSearch in Eureka ↗ |
| Plaintiff counsel | Cameron Paul Clark | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Jenny L. Colgate | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Kristen J. Logan | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Sharon L. Davis | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Steven Lieberman | Attorney | Counsel for HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing HQ Specialty Pharma, Corp.Search in Eureka ↗ |
| Defendant counsel | Anne Shea Gaza | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Brett Garrison | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel G. Mackrides | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy J. Edwards | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Samantha G. Wilson | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Steven A. Maddox | Attorney | Counsel for Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Amneal Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s phrasing is precise and commercially significant. The injunction is structured as a positive covenant — Amneal is ‘enjoined from making, having made, importing, using, offering for sale, or selling’ the Amneal Products — tracking standard permanent injunction language and covering the full chain of commercial activity. The explicit carve-out ‘unless licensed by Plaintiffs’ preserves a future monetisation path. The damages waiver for pre-August 2025 sales, combined with the no-merits-adjudication clause, suggests a negotiated trade: Amneal accepted forward-looking market exclusion in exchange for plaintiffs releasing retrospective financial exposure and avoiding the risk of patent invalidation at trial.
US10130646B1 — Terminally Sterilized Calcium Gluconate Injection Bag
US10130646B1 (application number US15/868705, filed January 2018) protects a formulation or manufacturing process covering terminally sterilized Calcium Gluconate in sodium chloride injection bag products. Terminal sterilisation — applying a sterilisation cycle to the final sealed container — is a regulatory and safety differentiator in the IV pharmaceutical market, as it reduces contamination risk compared to aseptic fill-finish processes. The patent’s B1 designation indicates it issued without post-grant amendment, suggesting the claims were accepted substantially as filed.
Calcium Gluconate IV is an essential medicine used in emergency and critical care settings — hypocalcaemia, hyperkalemia management, and calcium-channel blocker overdose protocols. A patent covering the terminally sterilized bag format controls a commercially significant delivery mechanism in the hospital and ICU procurement market. For competing generic manufacturers, the ‘646 patent represents a barrier to a high-demand, relatively concentrated product category. The consent judgment’s injunction confirms the patent is being actively enforced, raising the litigation risk profile for any company with a development programme in this space.
Should you run an FTO analysis against US10130646B1?
Any pharmaceutical or contract development and manufacturing organisation (CDMO) with a programme in terminally sterilized Calcium Gluconate or analogous alkaline earth metal salt IV bag products should treat this patent as a live enforcement risk. The consent judgment — entered August 2025 with court-retained jurisdiction — confirms the patent holder is prepared to litigate, negotiate injunctions, and enforce compliance. R&D teams should assess whether their formulation, sterilisation process, or container system falls within the ‘646 patent’s claim scope before progressing toward an IND or NDA/ANDA filing.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10130646B1 against your specific product parameters — sterilisation method, excipient concentrations, container type — and surface prior art or design-around pathways. Eureka’s litigation tracker also flags the active consent judgment and any subsequent enforcement activity, giving your regulatory and IP teams real-time visibility before capital is committed to manufacturing scale-up or market entry.
Run a freedom-to-operate analysis on US10130646B1 to assess your product’s exposure
Run FTO in Eureka →Similar sterile injectable pharmaceutical patent cases in Delaware District Court
Explore comparable infringement actions involving IV pharmaceutical formulation patents litigated in the District of Delaware with consent judgment or injunction outcomes.
What this case signals for the sterile injectable pharmaceutical IP landscape
The consent judgment structure used here is increasingly common in specialty pharma — understanding its mechanics protects both patent holders and would-be market entrants.
Consent judgments can deliver injunctions without merits exposure
Patent holders willing to waive past damages can extract court-entered injunctions that block competitors for the patent’s full remaining term. This strategy avoids the invalidity risk inherent in a full trial while achieving the primary commercial objective — market exclusivity — backed by judicial enforcement authority.
The ‘no merits adjudication’ clause matters for future challengers
Because the consent judgment explicitly states it is not an adjudication on the merits, the ‘646 patent’s validity and infringement scope remain legally untested. Future entrants in the terminally sterilized Calcium Gluconate IV bag space cannot rely on this proceeding as prior art for invalidity arguments — they must conduct independent analysis.
HQ v Amneal — key questions answered
The case closed on 12 August 2025 via a Stipulation and Consent Judgment. All claims and counterclaims were dismissed without prejudice — no merits ruling was made. Amneal was permanently enjoined from making, importing, or selling its terminally sterilized Calcium Gluconate in sodium chloride injection bag products in the US for the term of US10130646B1, unless licensed by the plaintiffs. Each party bore its own costs.
US10130646B1 covers terminally sterilized Calcium Gluconate in sodium chloride injection bag products. Terminal sterilisation of the final sealed container is a manufacturing and safety differentiator in the IV pharmaceutical segment. Plaintiffs alleged that Amneal’s competing Calcium Gluconate injection bag products infringed this patent. The consent judgment confirmed Amneal’s products fell within the commercial scope the patent holders sought to protect.
Dismissed without prejudice means neither infringement nor patent validity was adjudicated by the court. The consent judgment explicitly states it ‘shall not act as an adjudication on the merits.’ This preserves Amneal’s theoretical right to re-challenge the patent in a future proceeding and prevents the ruling from being used as collateral estoppel against other defendants. However, the injunction entered as part of the same order is a binding, judicially enforceable obligation on Amneal.
Under the consent judgment, Amneal is enjoined from making, importing, using, offering for sale, or selling its terminally sterilized Calcium Gluconate in sodium chloride injection bag products in the United States for the remaining term of US10130646B1 — unless licensed by HQ Specialty Pharma and WG Critical Care. The court retained jurisdiction to enforce compliance. Amneal could potentially re-enter the market through a licensing agreement with the plaintiffs or following patent expiry.
The damages waiver is consistent with a negotiated resolution in which the plaintiffs’ primary goal was prospective market exclusivity rather than retrospective monetary recovery. By waiving pre-August 2025 damages, plaintiffs likely secured Amneal’s agreement to the permanent injunction without the uncertainty and expense of a full damages trial. This trade-off also avoided the risk that a merits adjudication could have resulted in an invalidity finding that would have undermined the patent’s value against other potential infringers.
PatSnap Eureka searches patents and litigation data to answer instantly.